Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesFusion Antibodies PLC

Fusion Antibodies PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
5.5 GBX 0.00(0%)
Last update at 2026-10-27T16:09:00Z
VOLUME
302088
Market Cap
17.82M

Momentum Score

…

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.00
Low
6.00
High
52 Week Price Range
5.60
Low
21.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.50
Dividend Yield
-
Revenue TTM
1.60M
Revenue Per Share
0.01
Gross Profit TTM
0.35M
Debt / Equity
0.03
ROE
-164.37%
Net Debt
-0.34M
ROCE
-246.57%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -1.78M -2.29M -2.86M -1.33M -1.26M
Net income -1.71M -2.23M -2.60M -1.20M -2.90M
Selling general administrative 1.86M 2.25M 3.44M 3.82M 3.47M
Selling and marketing expenses 0.00M 0.47M - - -
Gross profit 0.43M -0.27M 0.57M 2.47M 2.02M
Reconciled depreciation 0.10M 0.22M 0.37M 0.75M 0.71M
Ebit -1.73M -2.28M -2.85M -1.32M -1.25M
Ebitda -1.62M -2.06M -2.48M -0.57M -0.53M
Depreciation and amortization 0.10M 0.22M 0.37M 0.75M 0.71M
Operating income -1.78M -2.29M -2.86M -1.32M -1.25M
Other operating expenses 3.74M 3.42M 5.76M 6.12M 5.41M
Interest expense 0.00M 0.01M 0.00M 0.01M 0.02M
Tax provision -0.06M -0.06M -0.26M -0.13M 1.64M
Interest income 0.01M 0.00M 0.00M 0.00M 0.00M
Net interest income 0.00M -0.00M -0.00M -0.01M -0.01M
Income tax expense 0.06M -0.06M -0.26M -0.13M 1.64M
Total revenue 1.97M 1.14M 2.90M 4.80M 4.17M
Total operating expenses 2.21M 2.24M 3.43M 3.79M 3.27M
Cost of revenue 1.53M 1.40M 2.33M 2.33M 2.14M
Total other income expense net 0.00M -0.00M -0.00M -0.01M -0.01M
Net income from continuing ops -1.71M -2.23M -2.60M -1.20M -2.90M
Net income applicable to common shares - - -2.60M -1.20M -2.90M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 1.32M 2.42M 2.06M 4.92M 5.83M
Intangible assets - - - 0.00M 0.00M
Other current assets 0.30M 0.05M 0.00M 1.65M 1.54M
Total liab 0.65M 0.63M 0.94M 1.23M 1.08M
Total stockholder equity 0.67M 1.79M 1.12M 3.68M 4.75M
Other current liab 0.21M 0.22M 0.40M 0.74M 0.65M
Common stock 4.20M 3.81M 1.04M 1.04M 1.02M
Capital stock 4.20M 3.81M 1.04M 1.04M 1.02M
Retained earnings -11.47M -9.77M -7.56M -5.00M -3.82M
Other liab - - 0.02M 0.02M 0.02M
Other assets - 0.00M - - -
Cash 0.36M 1.20M 0.20M 2.05M 2.69M
Total current liabilities 0.62M 0.58M 0.88M 1.21M 1.00M
Current deferred revenue - - -0.04M -0.07M -0.16M
Net debt -0.34M -1.16M -0.12M -1.98M -2.46M
Short term debt 0.04M 0.04M 0.04M 0.07M 0.16M
Short long term debt total 0.02M 0.04M 0.07M 0.07M 0.23M
Other stockholder equity 7.94M 7.74M 6.52M 3.96M 2.80M
Property plant equipment - - 0.38M 0.63M 1.12M
Total current assets 1.26M 2.26M 1.69M 4.28M 4.71M
Net tangible assets - - 1.12M 3.68M 4.75M
Net receivables 0.33M 0.56M 0.95M 1.65M 0.78M
Inventory 0.27M 0.46M 0.54M 0.58M 0.48M
Accounts payable 0.37M 0.28M 0.48M 0.47M 0.34M
Common stock total equity - - - - 1.02M
Non currrent assets other - -0.00M -0.38M -0.63M -1.12M
Non current assets total 0.06M 0.16M 0.38M 0.63M 1.12M
Capital lease obligations 0.02M 0.04M 0.07M 0.07M 0.23M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -0.01M 0.00M -0.11M -0.26M -0.36M
Change to liabilities - - -0.30M 0.31M 0.01M
Total cashflows from investing activities -0.01M 0.00M -0.11M -0.26M -0.36M
Net borrowings -0.02M -0.03M 0.01M -0.16M -0.15M
Total cash from financing activities 0.53M 2.77M 0.00M -0.06M 2.65M
Net income -1.71M -2.23M -2.60M -1.20M -2.90M
Change in cash -0.84M 1.00M -1.85M -0.64M 1.15M
Begin period cash flow 1.20M 0.20M 2.05M 2.69M 1.54M
End period cash flow 0.36M 1.20M 0.20M 2.05M 2.69M
Total cash from operating activities -1.36M -1.77M -1.75M -0.33M -1.14M
Issuance of capital stock 0.56M 2.81M 0.00M 0.12M 2.81M
Depreciation 0.10M 0.22M 0.37M 0.75M 0.71M
Other cashflows from investing activities 0.01M 0.00M 0.00M 0.00M 0.00M
Change to inventory 0.19M 0.08M 0.05M -0.10M -0.14M
Change to account receivables -0.07M 0.13M 0.82M -0.08M -0.55M
Sale purchase of stock - - - - 2.81M
Other cashflows from financing activities -0.00M -0.01M 0.09M -0.01M -0.00M
Change to netincome - - -0.10M -0.00M 1.74M
Capital expenditures 0.01M 0.00M 0.11M 0.26M 0.36M
Change in working capital 0.12M -0.07M 0.57M 0.13M -0.69M
Stock based compensation 0.04M 0.09M 0.04M 0.02M 0.02M
Other non cash items 0.09M 0.22M 0.00M 0.01M 0.01M
Free cash flow -1.37M -1.77M -1.87M -0.58M -1.50M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FAB
Fusion Antibodies PLC		 -
-%		 5.50 - - 11.16 21.09 9.68 -7.01
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

Fusion Antibodies PLC

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.

Springbank Industrial Estate, Belfast, United Kingdom, BT17 0QL

44 28 9043 2800

https://www.fusionantibodies.com

24

Name Title Year Born
Mr. James Fair CFO, Company Sec. & Director 1966
Dr. Richard John Buick Ph.D. Chief Scientific Officer & Director 1976
Dr. Adrian Kinkaid Ph.D. CEO & Director NA
Prof. Jim Johnston Founder NA
Mr. Hugh Morgan Ph.D. Director of Operations NA
Dr. Paul Gerard Kerr Consultant 1973
Dr. Adrian Robert Kinkaid Ph.D. CEO & Director 1967
Mr. Stephen Barry Smyth Company Secretary, Interim CFO & Director 1974
Ms. Nicola Hamilton Operations Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 106.39
+7.88%
GRZ
CAD 4.80
+5.26%
CTC
CAD 226.00
+4.63%
CAE
CAD 40.63
+4.21%
FEC
CAD 7.26
+3.57%
FSZ
CAD 2.40
-15.79%
TF
CAD 4.56
-11.28%
ITR
CAD 2.71
-9.67%
LAR
CAD 5.23
-7.43%
BZ
CAD 4.00
-7.41%

Equity Sectors*

  • Basic Materials

    -2.89%

  • Communication Services

    +0.25%

  • Consumer Cyclical

    +0.37%

  • Consumer Defensive

    -0.02%

  • Energy

    -0.30%

  • Financial Services

    -1.06%

  • Healthcare

    -0.73%

  • Industrials

    -0.49%

  • Real Estate

    +0.22%

  • Technology

    -1.52%

  • Utilities

    +0.08%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…